Tradestie Institutional Equity Comparison Engine

LCTX vs PRME โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while PRME counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus PRME at N/M Forward P/E and -2584.2% operating margin (+243.9% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against PRME sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs PRME N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -2584.2% ยท YoY -61.0% vs +243.9%
Momentum & Technical Winner PRME
1Y -53.7% vs +8.2% ยท 52W Pos 4% vs 36%
Options & Structure Winner PRME
BREAKDOWN (100th %ile IV) vs BREAKDOWN (64th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
PRME NASDAQ
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.84
+0.52% 1D
Market Cap $851.8M
1M Return +0.79%
1Y Return +8.17%
Forward P/E N/M
Unified AI Score
41.2 / 100 SELL
Tech 15.0 Fund 45.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% PRME +8.17% Spread: +61.84 pp (PRME Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue PRME Revenue LCTX Op. Margin PRME Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $10M -1448.4% -17.9% PRME
FY2021 $0M N/A -1133.6% N/A LCTX
FY2022 $10M N/A -153.2% N/A LCTX
FY2023 $10M N/A -276.5% N/A LCTX
FY2024 $10M $0M -226.1% -6787.4% LCTX
FY2025 $10M $0M -251.6% -4498.1% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (7) vs PRME (3)
Institutional Metric LCTX PRME Criterion Row Winner
Market Capitalization Scale $212.1M $851.8M Larger Scale PRME
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +243.9% Higher Growth PRME
Operating Margin (TTM) Profitability -280.3% -2584.2% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -207.2% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 36% ($3โ€“$6) Stronger Trend PRME
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 2.48ฮฒ ยท 149% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs PRME Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PRME BREAKDOWN
16d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live PRME Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor PRME registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.